Agreement means drugmaker will pay higher rebates to the Medicaid program on
Mylan, the marker of the EpiPen, has agreed to pay the federal government a $465 million settlement after it allegedly overcharged government healthcare agencies for the medicine, according to a release from the firm. Mylan had unde...
EpiPen maker Mylan agreed to pay $465 million in a settlement with federal regulators over its pricing practices
Mylan said the settlement, after the government had said it improperly classified EpiPen as a generic drug, did not imply any admission of wrongdoing.
Mylan has become the latest poster child for pharmaceutical industry price-gouging